Autoimmunity induced by interferon-alpha therapy for chronic viral hepatitis. (Q33698258)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10424246%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

review article

1 reference

title

Autoimmunity induced by interferon-alpha therapy for chronic viral hepatitis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10424246%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

author

Franz Ludwig Dumoulin

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10424246%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

author name string

Leifeld L

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10424246%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

Sauerbruch T

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10424246%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

Spengler U

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10424246%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

publication date

1 June 1999

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10424246%20AND%20SRC:MED&resulttype=core&format=json

Biomedicine and Pharmacotherapy

10 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10424246%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

volume

53

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10424246%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

issue

5-6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10424246%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

page(s)

242-254

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10424246%20AND%20SRC:MED&resulttype=core&format=json

Non-organ specific autoantibodies associated with chronic C virus hepatitis.

10 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Haemolytic anaemia to the alpha-interferon treatment: a proposed mechanism

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Reversibility of thyroid dysfunction induced by recombinant alpha interferon in chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Antiphospholipid syndrome associated with immunotherapy for patients with melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Thyroid dysfunction and liver injury following alpha-interferon treatment of chronic viral hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Differential responsiveness to interferon-alpha in beta-cells and non-beta cells

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Efficacy of combined interferon and ribavirin for treatment of hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Interferon and prednisone therapy in chronic hepatitis C with non-organ-specific antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Longitudinal Study of Antibodies against Thyroid in Patients Undergoing Interferon-&alpha; Therapy for HCV Chronic Hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Acquired factor VIII inhibitor associated with chronic interferon-alpha therapy in a patient with haemophilia A.

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Mono-arthritis in a chronic hepatitis B patient after alpha-interferon treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Non-insulin-dependent diabetes mellitus developing during interferon-alpha therapy for chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Pneumonitis associated with natural and recombinant interferon alfa therapy for chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Development of transient autoimmune hepatitis during interferon treatment of chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Prospective study on thyroid autoimmunity and dysfunction related to chronic hepatitis C and interferon therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Extrahepatic immunologic features of chronic viral hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Primary biliary cirrhosis induced by interferon-α therapy for hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Thyroid abnormalities in chronic viral hepatitis and their relationship to interferon alfa therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Interferon-alpha therapy may induce insulin autoantibody development in patients with chronic viral hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

The type-I interferon receptor. The long and short of it.

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Immune thrombocytopenia and alpha-interferon therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Interferon treatment of refractory idiopathic thrombocytopenic purpura (ITP)

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

[Chronic hepatitis C in type-II cryoglobulinemia and cutaneous vasculitis]

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Hepatitis C virus-associated mixed cryoglobulinaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Liver failure due to recombinant alpha interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Side effects of alpha interferon in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Low doses of interferon alpha result in more effective clinical natural killer cell activation

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Insulin-dependent diabetes mellitus during alpha-interferon therapy for chronic viral hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon.

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Increased risk of autoimmune thyroid disease in hepatitis C vs hepatitis B before, during, and after discontinuing interferon therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Thyrotropin receptor antibodies following treatment with recombinant alpha-interferon in patients with hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Neurovisual complications of interferon-alpha therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Interferon inhibits the generation of allospecific suppressor T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Psoriasis induced by interferon-α

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Latent autoimmune hepatitis triggered during interferon therapy in patients with chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Interferon-induced psoriasis in a patient with chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Polyarteritis nodosa related to hepatitis B virus. A prospective study with long-term observation of 41 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Lymphocytic sialadenitis of Sjögren's syndrome associated with chronic hepatitis C virus liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

The spectrum of extrahepatic manifestations in hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

[Occurrence and significance of autoantibodies in the course of interferon therapy of chronic hepatitis C]

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Sarcoidosis after interferon therapy for chronic active hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Chronic hepatitis C complicated by Coombs-negative hemolytic anemia during interferon treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

A patient with chronic hepatitis C who simultaneously developed interstitial pneumonia, hemolytic anemia and cholestatic liver dysfunction after alpha-interferon administration.

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Sarcoidosis associated with interferon-alpha therapy for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

The treatment of chronic viral hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Fatal hepatic decompensation associated with interferon alfa. European concerted action on viral hepatitis (Eurohep)

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Psoriasis with articular involvement induced by interferon alfa

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Immune thrombocytopenia and interferon alfa

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Development of transient thyroid disease and reaction during treatment of chronic hepatitis C with interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Psoriasis induced at the injection site of recombinant interferons

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Antibodies to hepatitis C virus in autoimmune liver disease: evidence for geographical heterogeneity

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Liver cytosolic 1 antigen-antibody system in type 2 autoimmune hepatitis and hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Development of thyroid disease during therapy of chronic viral hepatitis with interferon alfa

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Exacerbation of type 2 diabetes mellitus during interferon-alfa therapy for chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Improvement of sarcoidosis under therapy with interferon-alpha 2b for chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Exacerbation of primary biliary cirrhosis during interferon-alpha 2b therapy for chronic active hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Neurovisual impairment: a frequent complication of alpha-interferon treatment in chronic viral hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Thyroid autoimmune disorders in patients with chronic hepatitis C before and during interferon-alpha therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Hepatitis C virus infection, alpha interferon therapy and thyroid dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Sustained hypothyroidism induced by recombinant alpha interferon in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Formation of antibodies to factor VIII in patients with hemophilia A who are treated with interferon for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Treatment of chronic type B hepatitis with recombinant alpha-interferon induces autoantibodies not specific for autoimmune chronic hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Hepatitis C virus antibodies in chronic active hepatitis: pathogenetic factor or false-positive result?

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

35-year-old patient with chronic myelogenous leukemia developing systemic lupus erythematosus after alpha-interferon therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Induction of interstitial pneumonitis during interferon treatment for chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Interferon therapy in liver/kidney microsomal antibody type 1-positive patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Exacerbation of thyroid autoimmunity by interferon alpha treatment in patients with chronic viral hepatitis: our studies and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Recurrence of sarcoidosis following interferon alpha therapy for chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Induction of antinuclear antibody after interferon therapy in patients with type-C chronic hepatitis: its relation to the efficacy of therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

A comparison of interferon-Con1 with natural recombinant interferons-alpha: antiviral, antiproliferative, and natural killer-inducing activities

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Does interferon-beta therapy induce thyroid autoimmune phenomena?

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Autoimmune chronic hepatitis exacerbated by alpha-interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Latent autoimmune thyroid disease in patients with chronic HCV hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Extrahepatic immunologic manifestations in chronic hepatitis C and hepatitis C virus serotypes

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Thyroiditis after treatment with interleukin-2 and interferon alpha-2a

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Autoimmunity and thyroid function in patients with chronic active hepatitis treated with recombinant interferon alpha-2a

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Anticardiolipin antibodies in chronic hepatitis C: implication of hepatitis C virus as the cause of the antiphospholipid syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Exacerbation of lichen planus during interferon alfa-2a therapy for chronic active hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Axonal neuropathy associated with interferon-α treatment for hepatitis C: HLA-DR immunoreactivity in Schwann cells

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Clinical toxicity of interferons in cancer patients: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Thyroid dysfunction can predict response to immunotherapy with interleukin-2 and interferon-2 alpha

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Digital vasculitis associated with interferon therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Antigen presentation by human monocytes: effects of modifying major histocompatibility complex class II antigen expression and interleukin 1 production by using recombinant interferons and corticosteroids

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Possible induction of systemic lupus erythematosus by interferon-α treatment in a patient with a malignant carcinoid tumour

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Multiple changes in thyroid function in patients with chronic active HCV hepatitis treated with recombinant interferon-alpha

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Cutaneous vasculitis associated with interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Primary hypothyroidism associated with interleukin-2 and interferon alpha-2 therapy of melanoma and renal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Development of systemic lupus erythematosus after interferon therapy for chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Induction of hyperthyroidism by interferon-alpha-2b

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Anti-LKM-1 antibodies determined by use of recombinant P450 2D6 in ELISA and western blot and their association with anti-HCV and HCV-RNA

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Necrotizing vasculitis associated with hepatitis C virus infection: successful treatment of vasculitis with interferon-alpha despite persistence of mixed cryoglobulinemia

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Interferon-induced chronic active hepatitis?

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Interferon-induced vitiligo in a patient with chronic viral hepatitis C infection

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Severe autoimmune hepatitis in a chronic myeloid leukemia patient treated with interferon alpha and with complete genetic response

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Prolonged thrombocytopenia following alpha-interferon for refractory immune thrombocytopenic purpura

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Induction of type I diabetes by interferon-alpha in transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Regulation of human peripheral blood monocyte DR antigen expression in vitro by lymphokines and recombinant interferons

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Efficacy and safety of interferon alfa therapy in chronic hepatitis C with autoantibodies to liver-kidney microsomes

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Systemic lupus erythematosus in a child receiving long-term interferon therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Autoantibodies against the human asialoglycoprotein receptor: effects of therapy in autoimmune and virus-induced chronic active hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Alpha-interferon-induced nodular rheumatoid arthritis in renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Clinical toxicity of interleukin-2.

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Occurrence of IDDM during interferon therapy for chronic viral hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Liver failure due to recombinant alpha interferon for chronic myelogenous leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Lupus-like autoimmune disease induced by interferon therapy for myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Anti-neutrophil antibodies in chronic hepatitis and the effect of alpha-interferon therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Suppression of thyroid function by interferon-alpha 2 in man.

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Characterization of anti-liver-kidney microsome antibody (anti-LKM1) from hepatitis C virus-positive and -negative sera

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Interferon action: effects of mouse alpha and beta interferons on rosette formation, phagocytosis, and surface-antigen expression of cells of the macrophage-type line RAW 309Cr.1.

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

Interstitial pneumonia caused by interferon-alpha in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2899%2980095-X

7 January 2021

10.1016/S0753-3322(99)80095-X

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10424246%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

1 reference